Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients

Intensive Care Medicine
Catherina LueckGernot Beutel

Abstract

Intensive care unit (ICU) admission of allogeneic hematopoietic stem cell transplant (HSCT) recipients is associated with relatively poor outcome. Since longitudinal data on this topic remains scarce, we analyzed reasons for ICU admission as well as short- and long-term outcome of critically ill HSCT recipients. A total of 942 consecutive adult patients were transplanted at Hannover Medical School from 2000 to 2013. Of those, 330 patients were at least admitted once to the ICU and included in this retrospective study. To analyze time-dependent improvements, we separately compared patient characteristics as well as reasons and outcome of ICU admission for the periods 2000-2006 and 2007-2013. The main reasons for ICU admission were acute respiratory failure (ARF) in 35%, severe sepsis/septic shock in 23%, and cardiac problems in 18%. ICU admission was clearly associated with shortened survival (p < 0.001), but survival of ICU patients after hospital discharge reached 44% up to 5 years and was comparable to that of non-ICU HSCT patients. When ICU admission periods were compared, patients were older (48 vs. 52 years; p < 0.005) and the percentage of ARF as leading cause for ICU admission decreased from 43% in the first to 30% in th...Continue Reading

References

Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Jan 1, 1989·Critical Care Medicine·S J DenardoP E Bellamy
Jan 1, 1988·Intensive Care Medicine·C TorrecillaE Dominguez de Villota
Mar 29, 2003·Intensive Care Medicine·Mitchell M LevyUNKNOWN International Sepsis Definitions Conference
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric PèneJean-Paul Mira
Jun 13, 2008·Critical Care : the Official Journal of the Critical Care Forum·Damon C ScalesDonald A Redelmeier
Jul 31, 2009·Cancer·Alois GratwohlUNKNOWN European Group for Blood and Marrow Transplantation and the European Leukemia Net
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Sep 13, 2011·Annals of Intensive Care·Elie AzoulayBekele Afessa
Apr 30, 2013·Critical Care : the Official Journal of the Critical Care Forum·Jack E ZimmermanWilliam A Knaus
Jun 12, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elie AzoulayVirginie Lemiale
Sep 24, 2013·Bone Marrow Transplantation·R BenzG Stussi
Jun 6, 2014·Intensive Care Medicine·Elie AzoulayMichael Darmon
Mar 1, 2012·Kidney International Supplements
Mar 24, 2015·Bone Marrow Transplantation·E LenglinéE Azoulay
Dec 22, 2015·The Lancet. Haematology·Alois GratwohlUNKNOWN Worldwide Network for Blood and Marrow Transplantation (WBMT)
Jun 25, 2016·Annals of Hematology·Andrew J UllmannUNKNOWN Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (Ge

❮ Previous
Next ❯

Citations

Mar 14, 2019·Intensive Care Medicine·Etienne LenglinéElie Azoulay
Feb 17, 2021·Medizinische Klinik, Intensivmedizin und Notfallmedizin·C Lueck, G Beutel
Jun 16, 2021·Medicina Intensiva·P M Olaechea AstigarragaUNKNOWN List of supervisors and units participating in the ONCOENVIN study, ordered by number of patients contributed to the epidemi
Apr 21, 2020·Medicina intensiva·P M Olaechea AstigarragaUNKNOWN Listado de responsables y unidades participantes en estudio ONCOENVIN ordenados por número de pacientes aportados al estudio
Sep 15, 2021·Intensive Care Medicine·Bruno L FerreyroLaveena Munshi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.